Saturday 17 October 2026
Export GPCR’s income statement to Excel — free account
Structure Therapeutics Inc. Sponsored ADR
GPCR Healthcare Biotechnology
In the quarter to June 2026, EPS fell 36.4% and free cash flow fell 119.2%, each against the same quarter a year earlier.
20.95
1.24
−5.59%
Follow GPCR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(25.28%) | (11.86%) | (15.00%) | (20.21%) | |
| (23.87%) | (11.35%) | (14.35%) | (19.17%) | ||
ROIC |
0.00% | (157.24%) | 0.00% | (1,371.78%) | |
Return on Tangible Assets |
(27.68%) | (9.33%) | (11.83%) | (16.37%) | |
Average Days of Receivables |
— | 0.00 | — | — | |
Free Cash Flow per Share |
(3.36) | (3.81) | (2.20) | (3.09) | |
Free Cash Flow |
(196.38) | (225.81) | (159.22) | (224.50) | |
Capital Expenditures |
(2.13) | (3.61) | (4.48) | (4.21) | |
| Other line items | |||||
Cash ROIC |
(12.52%) | (7.62%) | (5.48%) | (8.32%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.92 | 1.57 | 0.91 | 1.03 | |
Depreciation/Fixed assets |
0.17 | 0.25 | 0.62 | 0.81 | |
Capex/Depreciation |
(2.63) | (2.15) | (1.14) | (0.82) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.32) | (3.75) | (2.14) | (3.03) | |
Capex per Share |
(0.04) | (0.06) | (0.06) | (0.06) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates